Massachusetts General Hospital is considering the sale of its royalty interest in the Enbrel, Amgen blockbuster drug for rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer, and its eigenvalues royalty income. "Hide
by David S. Scharfstein, Darren R. Smart Source: Harvard Business School 9 pages. Publication Date: November 16, 2005. Prod. #: 206075-PDF-ENG
Related Case Solutions & Analyses:
The Drivers of Greenwashing
China s Challenge to Feed Its People
Bank of America: Mobile Banking
Working with Your Shadow Partner in Analyzing IT Strategic Planning
Cox Communications Inc.–1999
Note on the FDReview Process for Medical Devices
A Big (Double) Deal: Anadarko’s Acquisition of Kerr-McGee and Western Gas Resources
STRATEGIES FOR DEVELOPING VALUE ADDED TAX IN SAUDI ARABIA
Keirsey Style Personality – Self Assessment
Metapath Case
